HIV Research & Clinical Practice最新文献

{"title":"Coverage of short-course TB preventive therapy regime among people living with HIV registered at a public anti-retroviral therapy centre in Western India.","authors":"Dularikunwarba Zala, Kedar Mehta, Paragkumar Chavda, Faizali Godhrawala, Darsh Contractor, Sunil Nayak","doi":"10.1080/25787489.2026.2722757","DOIUrl":"https://doi.org/10.1080/25787489.2026.2722757","url":null,"abstract":"<p><strong>Introduction: </strong>Tuberculosis (TB) is a major cause of illness and death among people living with HIV. Early initiation of TB preventive therapy (TPT) is crucial for preventing TB infection. As per National AIDS Control Programme (NACP) guidelines, the newer short-course TPT regime-1HP (isoniazid plus rifapentine, once a day for 28 days) is recommended for people living with HIV from May 2024 in India.</p><p><strong>Objective: </strong>To determine the coverage and completion of a newer TPT regime among people living with HIV and factors associated with coverage of TPT, and calculate the incidence of active tuberculosis among those who received TPT at subsequent visits until the end of our study period.</p><p><strong>Methodology: </strong>The secondary data, including the clinical and sociodemographic profiles of all people living with HIV who walked in the ART centre of a tertiary care hospital, were collected over a year from September 2024 after receiving permission from the Institutional Human Ethics Committee. The data were entered into Microsoft Excel and analysed using IBM SPSS v25.</p><p><strong>Results: </strong>Among the 1611 people living with HIV attending the ART centre, 287 were eligible for TPT, of which 217 (75%) started the newer (1HP) regime, and 216 (99.5%) completed it. Only 1 person living with HIV discontinued TPT because of the development of urticaria. There was no significant association between coverage of TPT and the sociodemographic and clinical indicators except area of residence, where it was significantly higher among people living with HIV residing in rural areas as compared to urban areas.</p><p><strong>Conclusion: </strong>The coverage of the newer short-course TPT regime (1HP) was 75%, and the completion rate was 99.5%. TPT coverage was high among people living with HIV residing in rural areas. TB incidence of 0.46% was recorded among those who received the newer TPT regimens.</p>","PeriodicalId":13165,"journal":{"name":"HIV Research & Clinical Practice","volume":"27 1","pages":"2722757"},"PeriodicalIF":2.1,"publicationDate":"2026-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148818243","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Successful initiation of fully parenteral antiretroviral therapy in a treatment-naïve person with HIV-1 infection and intestinal failure.","authors":"Krystof Sram, Hanus Rozsypal, Stanislav Sevela, Jakub Lhotan, David Jilich","doi":"10.1080/25787489.2026.2657707","DOIUrl":"10.1080/25787489.2026.2657707","url":null,"abstract":"<p><strong>Introduction: </strong>In patients with severe surgical and gastrointestinal complications, standard oral combination antiretroviral therapy (ARV) may be temporarily impossible. Long-acting cabotegravir/rilpivirine (CAB/RPV LA) is approved for virologically suppressed individuals pretreated with oral therapy, but data on its use in treatment-naïve, critically ill patients with absent enteral absorption are extremely limited.</p><p><strong>Clinical presentation: </strong>We report a 26-year-old male admitted with fulminant hypertriglyceridaemic necrotizing pancreatitis complicated by abdominal compartment syndrome, multiple laparotomies, open abdomen with enteric fistulae, short bowel syndrome type I, chronic intestinal failure requiring parenteral nutrition, portal vein thrombosis, and prolonged intensive care. HIV-1 infection was diagnosed early (HIV RNA 5,000 copies/mL; CD4+ 780 cells/µL). Within three months, HIV RNA rose to 320,000 copies/mL and CD4+ declined to 570 cells/µL. Given absent gastrointestinal passage, standard ARV was initially deferred, but rapid virological rebound necessitated urgent treatment. An off-label fully parenteral regimen was initiated: intravenous zidovudine (AZT) with intramuscular CAB/RPV LA. Therapy was well tolerated alongside surgery, parenteral nutrition, antimicrobials, and anticoagulation. HIV RNA decreased to <20 copies/mL within 65 days and remained suppressed, with CD4+ recovery. Intravenous AZT was discontinued after 35 days, and CAB/RPV LA continued as maintenance during recovery and home parenteral nutrition.</p><p><strong>Discussion: </strong>Fully parenteral ARV, including CAB/RPV LA, may provide a safe and effective bridge to durable viral suppression in patients with absolute contraindications to oral therapy, warranting further evaluation.</p>","PeriodicalId":13165,"journal":{"name":"HIV Research & Clinical Practice","volume":"27 1","pages":"2657707"},"PeriodicalIF":2.1,"publicationDate":"2026-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147653964","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring HIV self-testing and implementation determinants among migrants: perspectives from West, East, Central, and Southern African migrants and key informants in the Netherlands.","authors":"Oladipupo Shobowale, Kai J Jonas, Sarah E Stutterheim","doi":"10.1080/25787489.2026.2629083","DOIUrl":"10.1080/25787489.2026.2629083","url":null,"abstract":"<p><strong>Background: </strong>HIV self-testing (HIVST) has the potential to increase testing uptake among populations underserved by facility/clinic-based services, including African migrants in Europe. However, research on HIVST among African migrants in Europe and other high-income countries remains limited.</p><p><strong>Objective: </strong>To explore perspectives on HIVST, identify barriers and facilitators to uptake, and provide recommendations to inform effective implementation among African migrants in the Netherlands.</p><p><strong>Methods: </strong>Between February 2021 and May 2023, semi-structured interviews were conducted with 26 African migrants and 13 key informants, including healthcare providers (general practitioners, HIV specialists, testing service providers), policy and research professionals, and migrant community representatives. Data were analyzed using an inductive thematic approach. The Consolidated Framework for Implementation Research (CFIR) was applied post hoc to contextualize study findings within a broader implementation context.</p><p><strong>Results: </strong>Participants' perspectives on HIVST centered on three themes: enhanced autonomy in decision-making and testing processes; navigating autonomy and support for self-testing and care linkage; and HIVST within the Dutch context and prevention landscape. Factors potentially influencing successful uptake and implementation were identified across multiple CFIR domains, including perceived relative advantage over facility/clinic-based testing, evidence on reliability, and procedural complexity (Innovation Characteristics); low self-efficacy, self-testing and linkage to care support needs (Individual Characteristics); HIV stigma, limited awareness and low visibility of HIVST (Outer Setting); and perceived incompatibility with existing healthcare systems (Inner Setting).</p><p><strong>Conclusions: </strong>Although HIVST can address key testing barriers among African migrants, targeted implementation strategies are needed to guarantee equitable access, proper use, and optimal outcomes. These include enhanced dissemination of HIVST information, normalization of HIV testing and self-testing, provision of person-centered support, and establishing clear pathways for timely care linkage when required.</p>","PeriodicalId":13165,"journal":{"name":"HIV Research & Clinical Practice","volume":"27 1","pages":"2629083"},"PeriodicalIF":2.1,"publicationDate":"2026-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146179276","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acceptability and preferences regarding long-acting injectable antiretroviral therapy among people with HIV in Pakistan.","authors":"Muhammad Wasay Shahid, Masood-Ur- Rehman, Faizur Rehman, Mehran Riaz, Malik Muhammad Umair, Nasim Akhtar, Musarat Jabeen, Ali Ahmed","doi":"10.1080/25787489.2026.2635223","DOIUrl":"10.1080/25787489.2026.2635223","url":null,"abstract":"<p><strong>Background: </strong>Long-acting injectable antiretroviral therapy (LAI-ART) is an emerging alternative to daily oral ART, offering the potential to improve adherence, reduce dosing frequency, and alleviate treatment fatigue among people with HIV. There is limited evidence on its real-world acceptability, feasibility, and implementation challenges in low- and middle-income countries, such as Pakistan, where structural barriers and health system limitations may influence uptake.</p><p><strong>Objective: </strong>This study explores the perspectives on the feasibility and acceptability of LAI-ART among people currently receiving oral ART in Pakistan.</p><p><strong>Methods: </strong>A qualitative study was conducted from November 2024 to January 2025, involving in-depth interviews from people in the ART center in Islamabad and community-based organizations, and one focus group discussion (FGD) with participants who are actively engaged in community-based peer advocacy across Pakistan. The data were analyzed using conventional thematic analysis with inductive coding.</p><p><strong>Results: </strong>We conducted interviews with 37 participants, with one-to-one discussions with 31 people with HIV and 6 participants in FGD. Participants perceived LAI-ART as beneficial due to the elimination of pill burden, improved adherence, fewer side effects, lesser logistical demands, and greater privacy. However, injection-related adverse events, longer clinic waiting times, and limited availability were key barriers to its implementation. Those unwilling to adopt LAI-ART cited trust in oral ART, the convenience of multi-month refills, concerns of reduced adherence, work-related constraints.</p><p><strong>Conclusion: </strong>LAI-ART is acceptable to people with HIV in Pakistan, offering adherence and privacy benefits. However, successful implementation depends on addressing concerns around safety, supply, and access through responsive, stigma-free, and people-centered care models.</p>","PeriodicalId":13165,"journal":{"name":"HIV Research & Clinical Practice","volume":"27 1","pages":"2635223"},"PeriodicalIF":2.1,"publicationDate":"2026-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147270785","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Subclinical cardiovascular risk among adolescents with HIV in Tanzania: the role of sleep behaviour and antiretroviral regimen on arterial stiffness.","authors":"Tulla S Masoza, Caroline Andy, Megan Willkens, Sekela Kibona, Elizabeth Bundschuh, Robert N Peck, Samuel Kalluvya, Lindsey Reif","doi":"10.1080/25787489.2026.2725472","DOIUrl":"https://doi.org/10.1080/25787489.2026.2725472","url":null,"abstract":"<p><strong>Background: </strong>Data on arterial stiffness among adolescents with HIV remain limited, particularly in sub-Saharan Africa, where the HIV burden is high.</p><p><strong>Objective: </strong>We aimed to assess arterial stiffness among adolescents with HIV, compare these measures with already published measures, and investigate factors associated with arterial stiffness.</p><p><strong>Methods: </strong>A cross-sectional study among adolescents with HIV aged 10-17 years was conducted. Carotid-femoral pulse wave velocity (cfPWV) was measured to assess arterial stiffness using the SphygmoCor System (AtCor Medical), defined as a cfPWV ≥  the 90^th percentile. Least absolute shrinkage and selection operator (LASSO) regression, followed by multivariable linear regression, was performed to determine associated factors.</p><p><strong>Results: </strong>Among 416 adolescents with HIV in Tanzania (mean age 14 years; 53% male), 9.6% (95% CI: 7.0-13.0) had a cfPWV ≥ the 90^th percentile. The mean cfPWV in this cohort (4.77 ± 0.65 m/s) was lower than the estimates reported in several cohorts of adolescents with HIV in high-income countries and comparable to that reported in some cohorts in sub-Saharan Africa. Considering age, body mass index, and blood pressure as a priori confounders in multivariable analyses, higher cfPWV was independently associated with shorter sleep duration (<i>β</i> -0.04 per hour; 95%CI: -0.08, 0.0; <i>P</i> = 0.046), prolonged sleep latency ≥ 15 min (<i>β</i> 0.18; 95%CI: 0.05, 0.31; <i>P</i> = 0.006) and current use of a protease inhibitor antiretroviral regimen (<i>β</i> 0.3; 95%CI: 0.00, 0.61; <i>P</i> = 0.049).</p><p><strong>Conclusion: </strong>Early screening for arterial stiffness among adolescents with poor sleep behaviours, prior exposure to protease inhibitor-based regimens, and traditional CVD risk factors such as high BMI and blood pressure may provide an opportunity for early intervention through targeted lifestyle changes.</p>","PeriodicalId":13165,"journal":{"name":"HIV Research & Clinical Practice","volume":"27 1","pages":"2725472"},"PeriodicalIF":2.1,"publicationDate":"2026-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148891511","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Perceptions of young people living with HIV and caregivers in Botswana on analytical treatment interruption studies: a qualitative approach.","authors":"Catherine K Koofhethile, Poloko Kebaabetswe, Ontlametse T Choga, Fikile Ditshweu, Pearl Ntshonga, Bonolo R Molefe, Oganne Batlang, Patrick Mokgethi, Tsholofelo Mosielele, Phenyo Sabone, Pearl Kgoreletso, Amantle Gouwe, Keitumetse Mosepele, Rashida Majola, Dorcas Maruapula, Kaelo Seatla, Wonderful Choga, Gbolahan Ajibola, Joseph Makhema, Gaerolwe Masheto, Xu Yu, Sikhulile Moyo, Mathias Lichterfeld, Shahin Lockman, Roger Shapiro","doi":"10.1080/25787489.2026.2673739","DOIUrl":"10.1080/25787489.2026.2673739","url":null,"abstract":"<p><strong>Background: </strong>Current research suggests that post-treatment HIV control may be possible for some people following antiretroviral treatment (ART) interruption. Although closely monitored analytic treatment interruption (ATI) studies can be performed safely and are crucial to determine who may no longer require ART, currently it is unknown how acceptable these studies will be in Botswana.</p><p><strong>Aim: </strong>To determine the knowledge, attitudes and acceptability of ATI-inclusive studies in Botswana.</p><p><strong>Methods: </strong>We employed a non-randomized purposive design to recruit study participants. We conducted face-to-face open-ended interviews with 12 young people living with HIV and 8 caregivers, 8 healthcare providers and 4 community advocates in Gaborone and Palapye.</p><p><strong>Results: </strong>Thirty-two (32) participants consented to be interviewed. The median age of young people living with HIV was 29 years. All young people living with HIV indicated that they were on ART and acknowledged the benefits of being on ART. All young people living with HIV were unaware of ATIs, whereas 6 out of 8 caregivers, 6 out of 8 healthcare providers and 2 out of 4 community advocates had never heard of ATIs. Most participants found ATI research to be acceptable and believed that it would be beneficial provided there were adequate risk mitigations in place.</p><p><strong>Conclusions: </strong>ATI studies were acceptable to both young people living with HIV and their caregivers. There was limited knowledge about ATI, highlighting a need to inform communities and health care providers on the scientific aspects of ATI and HIV cure research.</p>","PeriodicalId":13165,"journal":{"name":"HIV Research & Clinical Practice","volume":"27 1","pages":"2673739"},"PeriodicalIF":2.1,"publicationDate":"2026-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13439527/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147981475","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Participant experiences of stopping ART as part of a clinical trial; findings from a qualitative study within the RIO trial in the United Kingdom.","authors":"Jesal Gohil, Marcelino Molina, Ali Ahmed, Simon Collins, Ming Jie Lee, Tamara Elliott, Gary Whitlock, Marta Boffito, Piyumika Godakandaarachi, Julie Fox, Amanda Clarke, Sabine Kinloch-de Loes, Sarah Pett, Alison Uriel, Irvine Mangawa, Kyle Ring, Chloe Orkin, Rebecca Sutherland, Lisa Hamzah, Paola Cicconi, John Frater, Matthew Grundy-Bowers, Karine Dubé, Sarah Fidler","doi":"10.1080/25787489.2026.2739700","DOIUrl":"https://doi.org/10.1080/25787489.2026.2739700","url":null,"abstract":"<p><strong>Introduction: </strong>Evaluation of the efficacy of immunotherapeutic strategies aimed at achieving durable antiretroviral treatment (ART)-free control within a clinical trial relies on analytical treatment interruptions (ATIs). ATIs involve stopping ART to assess post-intervention efficacy with frequent viral load monitoring. These trials rely on participant commitment but also involve uncertainty about the timing and experience of viral rebound, transmission risk, and impacts on personal and sexual relationships. Understanding participants' lived experiences is critical to participant involvement and retention and to designing ATI studies that are ethical, feasible, and acceptable.</p><p><strong>Methods: </strong>We conducted a qualitative study involving semi-structured interviews with 20 cisgender men living with HIV enroled in the phase 2 double-blinded randomised placebo-controlled RIO trial of HIV-specific broadly neutralising antibodies between January and May 2025 in the United Kingdom. We transcribed, coded and analysed the interviews using thematic analysis.</p><p><strong>Results: </strong>The participants described being motivated by scientific altruism but had worries about stopping ART. During the ATI, participants found breaking their daily pill-taking routine challenging, yet a majority described feelings of liberation thereafter. The participants preferred once weekly viral load testing, as it reassured safety, which was coupled with support from researchers, who buffered anxiety during periods of viral rebound. ATIs had a notable impact on personal relationships, including avoidance of dating, reduced intimacy and sexual pleasure while off ART. Easy access for partners without HIV to free PrEP, PEP, and condoms was welcomed by all participants. Restarting ART was difficult following the ATI, but was resolved with pre-trial preparation supporting adherence. The participants with lengthy ATIs remained enthusiastic but were challenged by uncertainty that required adjustment of their life plans. Finally, participants expressed mixed views regarding the use of placebo arms in trials but accepted a second ATI period after receiving broadly neutralising antibodies open-label.</p><p><strong>Conclusions: </strong>Participants described being part of an ATI trial as both liberating and demanding. The findings indicate that acceptability is influenced by predictable, frequent weekly HIV viral load monitoring, timely results communication, and access to free prevention, with clear concerns about relationship impacts during viral rebound, and clearly communicated pre-defined ART restart criteria.</p>","PeriodicalId":13165,"journal":{"name":"HIV Research & Clinical Practice","volume":"27 1","pages":"2739700"},"PeriodicalIF":2.1,"publicationDate":"2026-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149108830","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Why addressing HIV stigma should be our number one priority in the HIV response.","authors":"Sarah E Stutterheim","doi":"10.1080/25787489.2026.2638007","DOIUrl":"10.1080/25787489.2026.2638007","url":null,"abstract":"<p><p>If we are to achieve the UNAIDS 95-95-95 goals, and eventually eradicate HIV, we need to prioritise stigma reduction, and we need to be smart about how we do it. This position paper gives an overview of the ways in which HIV stigma impacts the cascade of care outcomes, provides guidance for effective stigma reductions interventions, and delineates priorities for understanding and addressing stigma in the HIV response. It makes clear that various forms of stigma deleteriously impact prevention and testing, linkage to care, initiation and adherence to antiretroviral treatment, and viral suppression, and it describes stigma reduction methods for public stigma, self-stigma, and structural stigma. It furthermore argues that stigma interventions should be systematically developed, theory- and evidence-based, tailored to context, and co-designed and co-implemented with recipient populations. Lastly, this paper argues for a better measurement of stigma, not by seeking consensus on construct definitions and corresponding measures but rather through the transparent reporting of definitions and their operationalisations.</p>","PeriodicalId":13165,"journal":{"name":"HIV Research & Clinical Practice","volume":"27 1","pages":"2638007"},"PeriodicalIF":2.1,"publicationDate":"2026-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147305091","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"\"If I've got this, then let me use it to try to help and change it.\" Perspectives on HIV cure and research participation: a qualitative interview study of women and migrants living with HIV in Australia.","authors":"Weerasuria Mihiri, Chong Susan Cs, Machon Kirsten, Ellis Heather, Woolley Ian John, Power Jennifer, Lau Jillian Sy","doi":"10.1080/25787489.2026.2743984","DOIUrl":"https://doi.org/10.1080/25787489.2026.2743984","url":null,"abstract":"<p><strong>Background: </strong>People living with HIV who are women and/or migrants are underrepresented in cure-related trials, raising equity, acceptability, and research generalisability concerns (including those related to HIV clade representation).</p><p><strong>Objective: </strong>Explore perspectives of HIV cure-related research amongs a cohort of women and migrants people living with HIV.</p><p><strong>Methods: </strong>Alongside HIV community groups, people living with HIV who identified as women and/or spoke a non-English language at home attending infectious diseases clinic at a tertiary academic hospital in Melbourne, Australia were interviewed. These explored cure research knowledge and perceptions, participation motivations/barriers, and trial design preferences. Interviews were audio-recorded, transcribed, and analysed thematically using an inductive approach.</p><p><strong>Results: </strong>Twenty interviews were completed (four with interpreters). Median age was 50.5 years (range 32-75). Fourteen participants identified as female and six as male; 15 were born outside Australia. HIV cure research awareness was limited. Most described ongoing physical, psychological, and social impacts from HIV, reinforcing desire for a cure. Established relationships with HIV clinicians were central to research engagement. Additional motivators included personal benefit and altruism. Conversely, perceived risks, time commitments, and fear of unwanted sharing of HIV status were barriers. Participants emphasised culturally appropriate communication and meaningful community involvement is needed.</p><p><strong>Conclusion: </strong>These participants view cure research with hope and hesitation. Equitable participation requires addressing structural and cultural barriers, improving communication, and embedding community perspectives into research. HIV providers are vital partners, working alongside communities to support informed decision-making, and help ensure that the path toward an HIV cure is shaped by, and for, those it serves.</p>","PeriodicalId":13165,"journal":{"name":"HIV Research & Clinical Practice","volume":"27 1","pages":"2743984"},"PeriodicalIF":2.1,"publicationDate":"2026-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149108770","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Navigating viral load information flow and provider decision-making for adolescent clients at HIV clinics in Kenya.","authors":"Deepa Oja, Christine Kundu, Alvin Onyango, Cyrus Mugo, Irene Njuguna, Hellen Morra, Dalton Wamalwa, Jillian Pintye, Grace John-Stewart, Molly R Altman, Pamela Kohler","doi":"10.1080/25787489.2026.2650034","DOIUrl":"10.1080/25787489.2026.2650034","url":null,"abstract":"<p><strong>Background: </strong>Achieving viral suppression goals for adolescents with HIV requires multifaceted strategies, including efficient and effective health systems to routinely monitor HIV viral load (VL) and support adolescents when adherence falters.</p><p><strong>Objective: </strong>This study aimed to identify where gaps in information flow occur in return of HIV VL results to clinics and adolescents and to explore how providers determine 'good adherence' prior to confirmation of virological failure.</p><p><strong>Methods: </strong>Four focus group discussions and ten in-depth interviews were conducted with purposively selected healthcare workers (<i>n</i> = 39) from various phases of VL information flow. We used thematic analysis to identify themes.</p><p><strong>Results: </strong>Themes consisted of individual- and family-level challenges, facility-level barriers, supply chain constraints affecting laboratory-related delays, client-specific factors impacting dissemination of VL results, reluctance to repeat VL until adherence challenges are resolved.</p><p><strong>Conclusion: </strong>The identified themes highlighted that individual, social, and health systems factors were perceived as contributing to success or delay in the ability to obtain timely VL results and repeat confirmatory VL testing.</p>","PeriodicalId":13165,"journal":{"name":"HIV Research & Clinical Practice","volume":"27 1","pages":"2650034"},"PeriodicalIF":2.1,"publicationDate":"2026-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13232530/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147591913","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}